



## Immunotherapy: New Prospective in the Treatment of Ovarian Cancer

Guest Editors:

**Dr. Chiara Napoletano**

Department of Experimental  
Medicine, "Sapienza" University  
of Rome, Viale Regina Elena 324,  
00161 Rome, Italy

**Prof. Dr. Filippo Bellati**

Department of Gynecology,  
Sant'Andrea Hospital, Sapienza  
University of Rome, Rome, Italy

Deadline for manuscript  
submissions:

**closed (31 August 2021)**

### Message from the Guest Editors

Ovarian cancer still remains the major unresolved problem of gynaecologic oncologists in terms of efficient treatment.

Due to the great importance that immunological fitness has in the clinical outcome, large efforts have been made to develop new immunotherapeutic strategies to be administered alone or in combination with standard therapies. In addition to the development of novel immunotherapy approaches, several questions that could impact the long-term results of any immunological intervention need further investigation. Timing of immunological treatment and integration with the several currently adopted therapeutic strategies and drug administration approaches (administration schedule, intravenous vs intraperitoneal vs intranodal, dosage, etc.) represent critical issues that need to be resolved.

This Special Issue is focused on novel therapeutic strategies (immunotherapy alone or combined with standard therapies or other agents), innovative administration schedule, new immune targets, novel ideas and approaches to further improve the therapeutic efficacy of immunotherapy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)